• Raphael Borie, Aurelien Justet, Guillaume Beltramo, Effrosyni D Manali, Pauline Pradère, Paolo Spagnolo, and Bruno Crestani.
• APHP, Bichat Hospital, Department of Pneumology A, Centre de competence des maladies pulmonaires rares, DHU Fire, Paris, France.
• Respirology. 2016 May 1; 21 (4): 615-25.

AbstractIdiopathic pulmonary fibrosis (IPF) is a deadly disease with a median survival of approximately three years in historical cohorts. Despite increased knowledge of disease pathophysiology and selection of more targeted therapy, main clinical trials yielded negative results. However, two agents, pirfenidone and nintedanib, were recently shown to be effective in IPF and received marketing authorization worldwide. Both drugs significantly reduce functional decline and disease progression with an acceptable safety profile. Yet, none of these drugs actually improves or even stabilizes the disease or the symptoms perceived by the patient. Several other treatments and combinations are currently tested, and many more are ready for clinical trials. Their completion is critical for achieving the ultimate goal of curing patients with IPF. © 2016 Asian Pacific Society of Respirology.

24 keywords...

hide…